A drug tested unsuccessfully in patients with prostate cancer may actually benefit patients who suffer from neuroendocrine prostate tumors, a particularly lethal form of the disease. Weill Cornell Medical College researchers and others found that the aurora kinase inhibitor PHA-739358 appeared to work well against human neuroendocrine prostate cells in the lab. The drug also shrank neuroendocrine tumors in mice. Details are published in the latest issue of the journal Cancer Discovery. Release